Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Abraham J. Wu, V. Rusch, Andreas Rimner, Bernard J. Park, Harper Hubbeling, E. Ziv, Charles B. Simone, Daniel R. Gomez, Christina Falcon, Annemarie F. Shepherd, A. Drilon, Daphna Y. Gelblum, Narek Shaverdian, Noura J. Choudhury
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e438-e439
Purpose/Objective(s) Local therapy (LTX) prolongs progression-free and overall survival (OS) in patients with oligometastatic non-small cell lung cancer. We previously reported substantial LTX benefit in time to progression or next therapy (TTP/TTNT)
Autor:
James S. Hardwick, Alice T. Shaw, Anna F. Farago, Aaron N. Hata, Lorin A. Ferris, Diane Tseng, Katherine Schultz, Beow Y. Yeap, Luc Friboulet, Justin F. Gainor, Satoshi Yoda, Donghui Huang, Leila Dardaei, Zofia Piotrowska, Ibiayi Dagogo-Jack, A. John Iafrate, Jessica J. Lin, Harper Hubbeling, Mari Mino-Kenudson
Publikováno v:
JCO Precision Oncology. :1-13
Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transiti
Autor:
Jochen K. Lennerz, Jessica J. Lin, Theodore O. Johnson, Charlotte E. Lee, Justin F. Gainor, Beow Y. Yeap, Harper Hubbeling, Ibiayi Dagogo-Jack, Alice T. Shaw
Publikováno v:
Journal of Clinical Oncology. 38:9611-9611
9611 Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC), including in patients (pts) previously tre